| Name | benzodiazepine receptor (protein family or complex) |
|---|---|
| Synonyms | Benzodiazepine receptor; benzodiazepine (BDZ) receptor; BDZ receptor |
| Name | strychnine |
|---|---|
| CAS | strychnidin-10-one |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 8539344 | Molewijk HE, van der Poel AM, Olivier B: The ambivalent behaviour "stretched approach posture" in the rat as a paradigm to characterize anxiolytic drugs. Psychopharmacology. 1995 Sep;121(1):81-90. Finally, the 5-HT2C receptor antagonist ritanserine, the CCKA receptor antagonist devazepide, the CCKB receptor antagonist L-365.260 and the strychnine-insensitive site antagonist 7-Cl- were without effect on the behaviours in this paradigm using single doses. The benzodiazepine receptor agonists chlordiazepoxide, diazepam and alprazolam, the 5-HT1A receptor agonists flesinoxan and ipsapirone and the uptake inhibitor clomipramine selectively (no effect on crossings) reduced SAP. |
2(0,0,0,2) | Details |
| 9895039 | Kostowski W, Bienkowski P: Discriminative stimulus effects of neuropharmacological characterization. Alcohol. 1999 Jan;17(1):63-80. Substitution studies have shown that the complete substitution for may be exerted by certain -mimetic drugs acting through different sites within the (A)-benzodiazepine receptor complex (e.g., diazepam, pentobarbital, certain neurosteroids), gamma-hydroxybutyrate, and antagonists of the NMDA receptor. Further, some antagonists of strychnine-insensitive modulatory sites among the NMDA receptor complex (e.g., L-701,324) dose-dependently substitute for the discriminative stimulus. |
2(0,0,0,2) | Details |
| 11952420 | Menzikov SA, Menzikova OV: Effect of activators and blockers of ligand-regulated ion channels on the activity of the Cl-stimulated Mg2+-ATPase of the plasma membrane fraction from bream (Abramis brama L.) brain. Biochemistry. 2002 Feb;67(2):233-9. The activation of "basal" Mg (2+)-ATPase by neuromediators was decreased by blockers of the corresponding receptors (picrotoxin, strychnine, benztropine mesylate, and D-2-amino-5-phosphonovaleric acid). Agonists of the GABAa/benzodiazepine receptor--phenazepam (10 (-8)-10 (-4) M) and pentobarbital (10 (-6)-10 (-3) M)--activated the "basal" Mg (2+)-ATPase activity and decreased the Cl (-)-stimulated Mg (2+)-ATPase activity. |
1(0,0,0,1) | Details |
| 15056857 | Koo BS, Lee SI, Ha JH, Lee DU: Inhibitory effects of the essential oil from SuHeXiang Wan on the central nervous system after inhalation. Biol Pharm Bull. 2004 Apr;27(4):515-9. Preinhalation of the fragrance oil markedly delayed the appearance of pentylenetetrazole-induced convulsion, but showed weak activities on picrotoxin- and strychnine-induced convulsions, which implies this drug may inhibit the convulsion by GABAergic neuromodulation. This essential oil inhibited the binding of [(3) H] Ro15-1788, a selective antagonist for the benzodiazepine receptor and also the binding of [(3) H] flunitrazepam, a selective agonist for the receptor, in the presence of and NaCl, showing a positive shift, which suggested the strong possibility of the agonistic activity of the essential oil to the /benzodiazepine receptor complex in rat cerebral cortices. |
1(0,0,0,1) | Details |
| 7834364 | Drugan RC, Basile AS, Ha JH, Ferland RJ: The protective effects of stress control may be mediated by increased brain levels of benzodiazepine receptor agonists. Brain Res. 1994 Oct 24;661(1-2):127-36. |
1(0,0,0,1) | Details |
| 8813615 | Zhao TJ, Rosenberg HC, Chiu TH: Treatment with an antisense oligodeoxynucleotide to the GABAA receptor gamma 2 subunit increases convulsive threshold for beta-CCM, a benzodiazepine "inverse agonist', in rats. Eur J Pharmacol. 1996 Jun 13;306(1-3):61-6. Both antisense and sense oligodeoxynucleotide treatments slightly increased the threshold for strychnine seizures. The results suggest that antisense oligodeoxynucleotide treatment altered GABAA receptor composition and interfered with the actions of a benzodiazepine receptor ligand in vivo, and may provide a tool for studying regulation of receptor structure and function. |
1(0,0,0,1) | Details |
| 9004347 | Kawasaki K, Eigyo M, Ikeda M, Kihara T, Koike K, Matsushita A, Murata S, Shiomi T, Takada S, Yasui M: A novel benzodiazepine inverse agonist, S-8510, as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Nov;20(8):1413-25. Pharmacological actions of a novel benzodiazepine receptor ligand, S-8510 (2-(3-isoxazolyl)-3,6,7,9-tetrahydroimidazo [4,5-d] pyrano+ ++[4,3-b] monophosphate monohydrate), were examined in in vitro and in vivo studies. 2. S-8510 selectively potentiated pentylenetetrazol-induced convulsion without affecting minimal electroconvulsive shock- or strychnine-induced convulsion in ddY mice. 7. |
1(0,0,0,1) | Details |
| 12659934 | Trapani G, Latrofa A, Franco M, Carrieri A, Cellamare S, Serra M, Sanna E, Biggio G, Liso G: Alpidem analogues containing a or moiety as new anticonvulsant agents. Eur J Pharm Sci. 2003 Mar;18(3-4):231-40. Alpidem analogues containing a (1-3) or (4-6) moiety were synthesized and their interaction with the /benzodiazepine receptor complex at central (CBR) and peripheral (PBR) level was evaluated. However, compound 4 failed to interact with strychnine-sensitive Gly-binding sites. |
1(0,0,0,1) | Details |